← Back to Search

Monoclonal Antibodies

Tocilizumab + Atezolizumab for Non-Small Cell Lung Cancer

Phase 1 & 2

Recruiting

Led By Melina Marmarelis, MD, MSCE

Research Sponsored by Abramson Cancer Center of the University of Pennsylvania

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

ECOG PS 0-2

Advanced non-squamous NSCLC (Stage IV or recurrent after initial curative intent therapy) in adults age 18 or older

Must not have

Presence of a driver mutation that is susceptible to targeted therapy

Uncontrolled tumor related pain

Timeline

Screening 3 weeks

Treatment Varies

Follow Up from 1st dose of treatment until 1st radiologic disease progression, unequivocal clinical progression, or death due to any cause censored at the last scheduled disease assessment on study if no progression date registered, assessed up to 24 months.

Awards & highlights

No Placebo-Only Group

Summary

This trial is testing a new combination therapy to see if it is effective and safe in treating non-small cell lung cancer.

Who is the study for?

Adults over 18 with advanced non-squamous Non-Small Cell Lung Cancer (Stage IV or recurrent) who've had at least one prior therapy and were treated with a checkpoint inhibitor right before joining. They should be relatively fit (ECOG PS 0-2). Those with autoimmune diseases, severe past immunotherapy side effects, certain genetic mutations, brain metastases, another active cancer, or uncontrolled cancer pain can't join.

What is being tested?

The trial is testing the combination of two drugs: Tocilizumab and Atezolizumab for treating lung cancer that hasn't responded to first-line immune therapies. It aims to assess how safe and effective this drug duo is in managing the disease.

What are the potential side effects?

Potential side effects may include reactions related to the immune system such as inflammation in various organs, fatigue, possible worsening of pre-existing conditions like autoimmune diseases if not excluded from participation, and other common chemotherapy-related side effects.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I can take care of myself and perform daily activities.

Select...

I am 18 or older with advanced non-squamous NSCLC.

Select...

I have undergone at least one treatment for my condition.

Select...

I was treated with a checkpoint inhibitor before joining this trial.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:

Select...

My cancer has a mutation that can be treated with targeted therapy.

Select...

I have pain from my cancer that isn't relieved by treatment.

Select...

I haven't had severe side effects from previous immunotherapy.

Select...

My cancer has spread to my brain and is getting worse or hasn't been treated.

Select...

I have or had cancer spread to the lining of my brain and spinal cord.

Select...

I have a history of an autoimmune disease or idiopathic pulmonary fibrosis.

Select...

I am currently being treated for another type of cancer.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ from 1st dose of treatment until 1st radiologic disease progression, unequivocal clinical progression, or death due to any cause censored at the last scheduled disease assessment on study if no progression date registered, assessed up to 24 months.

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~from 1st dose of treatment until 1st radiologic disease progression, unequivocal clinical progression, or death due to any cause censored at the last scheduled disease assessment on study if no progression date registered, assessed up to 24 months.

This trial's timeline: 3 weeks for screening, Varies for treatment, and from 1st dose of treatment until 1st radiologic disease progression, unequivocal clinical progression, or death due to any cause censored at the last scheduled disease assessment on study if no progression date registered, assessed up to 24 months. for reporting.